OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
-10.93%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$126M
AUM Growth
+$126M
(+0.99%)
Cap. Flow
+$20.9M
Cap. Flow
% of AUM
16.63%
Top 10 Holdings %
Top 10 Hldgs %
41.51%
Holding
66
New
9
Increased
27
Reduced
13
Closed
10
Top Buys
| 1 |
iShares Biotechnology ETF
IBB
|
$6.07M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
$3.57M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$3.25M |
| 4 |
AstraZeneca
AZN
|
$2.74M |
| 5 |
Bristol-Myers Squibb
BMY
|
$2.13M |
Top Sells
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$5.35M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
$3.16M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
$1.76M |
| 4 |
Esperion Therapeutics
ESPR
|
$1.23M |
| 5 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$1.21M |
Sector Composition
| 1 | Healthcare | 85.85% |
| 2 | Financials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares Biotechnology ETF
IBB
$5.6B
| $6.07M | 3.35% | +20,000 | New | +$6.07M |
|
|
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.39M | 2.97% | 58,567 +6,167 | +12% | +$567K |
|
3
Incyte
INCY
$16.5B
| $5.23M | 2.89% | 47,400 +5,527 | +13% | +$610K |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $5.16M | 2.85% | 33,021 +11,547 | +54% | +$1.81M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $5.1M | 2.82% | 47,137 +8,762 | +23% | +$948K |
|
6
Biogen
BIIB
$19.4B
| $5.1M | 2.81% | 17,467 +6,213 | +55% | +$1.81M |
|
7
Alkermes
ALKS
$4.78B
| $5.1M | 2.81% | 86,864 +15,842 | +22% | +$929K |
|
|
MDVN
8
DELISTED
MEDIVATION, INC.
MDVN
| $5.03M | 2.78% | 118,372 +84,028 | +245% | +$3.57M |
|
9
Illumina
ILMN
$15.8B
| $4.98M | 2.75% | 28,334 +6,883 | +32% | +$1.21M |
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $4.94M | 2.73% | 10,627 +1,868 | +21% | +$869K |
|
11
Nektar Therapeutics
NKTR
$568M
| $4.87M | 2.69% | 444,258 +76,295 | +21% | +$836K |
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.8M | 2.65% | 124,558 +20,219 | +19% | +$780K |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.43M | 2.44% | 42,012 +6,113 | +17% | +$644K |
|
14
Bio-Techne
TECH
$8.5B
| $4.35M | 2.4% | 47,000 +13,000 | +38% | +$1.2M |
|
|
15
AstraZeneca
AZN
$248B
| $4.33M | 2.39% | 136,000 +86,000 | +172% | +$2.74M |
|
16
Mettler-Toledo International
MTD
$26.8B
| $4.33M | 2.39% | 15,200 +4,200 | +38% | +$1.2M |
|
17
Vertex Pharmaceuticals
VRTX
$100B
| $4.26M | 2.35% | 40,876 +5,600 | +16% | +$583K |
|
|
QGENF
18
DELISTED
QIAGEN NV
QGENF
| $4.13M | 2.28% | 160,000 +20,000 | +14% | +$516K |
|
19
Ionis Pharmaceuticals
IONS
$6.79B
| $4.1M | 2.26% | 101,401 +35,193 | +53% | +$1.42M |
|
|
CPHD
20
DELISTED
Cepheid Inc
CPHD
| $4.07M | 2.25% | 90,000 +26,365 | +41% | +$1.19M |
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.89M | 2.15% | 48,448 +13,469 | +39% | +$1.08M |
|
|
22
Agios Pharmaceuticals
AGIO
$2.19B
| $3.25M | 1.79% | +46,000 | New | +$3.25M |
|
|
23
Bristol-Myers Squibb
BMY
$96B
| $2.13M | 1.18% | +36,000 | New | +$2.13M |
|
24
Merck
MRK
$210B
| $2.03M | 1.12% | +41,000 | New | +$2.03M |
|
|
25
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $1.91M | 1.05% | 32,717 -20,851 | -39% | -$1.21M |
|